PURR.AI

Article 29 – Tecnimede Open Innovation Competition ’25

PURR.AI NAMED FINALIST IN PRESTIGIOUS TECNIMEDE OPEN INNOVATION COMPETITION ’25

PURR.AI is thrilled to be selected as one of the top 10 finalists in the Tecnimede Open Innovation Competition (TOIC2025), powered by HiSeedTech, spotlighting our cutting-edge AGELESS platform for neuro drug discovery.

The competition celebrates groundbreaking innovations, and PURR.AI stands out among the elite 10 finalists for revolutionising CNS drug development. Our selection highlights the platform’s potential to transform how pharma teams tackle central nervous system challenges.

AGELESS harnesses AI, machine learning, molecular simulations, and curated biomedical data to predict blood-brain barrier permeability and early-stage development risks with unprecedented accuracy. This powerful combination empowers researchers to make faster, data-driven decisions, slashing failure rates and paving the way for novel treatments in neurological diseases.

Competing alongside visionaries in the #TOIC2025 arena underscores PURR.AI’s leadership in #AIinPharma and #CNSTherapeutics. This milestone from Portugal fuels our drive to deliver disruptive solutions that bridge the gap from lab to life-changing therapies.

0
Would love your thoughts, please comment.x
()
x